跳转至内容
Merck
CN

SML1265

Sigma-Aldrich

波生坦 水合物

≥98% (HPLC)

别名:

4-(1,1-二甲基乙基)-N-[6-(2-羟基乙氧基)-5-(2-甲氧基苯氧基)[2,2'-联嘧啶]-4-基]-苯磺酰胺 一水合物, 4-叔丁基-N- [6-(2-羟基乙氧基)-5-(2-甲氧基-苯氧基)-[2,2´]-联嘧啶-4-基]-苯磺酰胺 一水合物, Ro-47-0203

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H29N5O6S · H2O
分子量:
569.63
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 5 mg/mL, clear (warmed)

储存温度

2-8°C

SMILES字符串

O=S(C1=CC=C(C(C)(C)C)C=C1)(NC2=NC(C3=NC=CC=N3)=NC(OCCO)=C2OC4=CC=CC=C4OC)=O.O

InChI

1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2

InChI key

SXTRWVVIEPWAKM-UHFFFAOYSA-N

应用

水合波生坦已用于细胞活力测定。此外,它还被用作钙瞬态分析的阳性对照。

生化/生理作用

已有发现证明,波生坦可减少肺中胶原蛋白沉积——在博来霉素诱导的肺纤维化大鼠模型中观察到此现象。
波生坦是一种内皮素受体拮抗剂。内皮素是一种有效的血管收缩药,因而成为治疗血管痉挛相关疾病(如蛛网膜下腔出血 (SAH) 和高血压)的临床关注拮抗剂。波生坦是一种双重内皮素受体拮抗剂,可有效治疗肺动脉高压(PAH),这是首个投放市场的同类产品。波生坦是 ETA 和 ETB 受体亚型(ETA 的 Ki 为4.7 nM,ETB 的 Ki为95 nM)的竞争性口服拮抗剂。

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Aquatic Chronic 3 - Repr. 2

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery.
Drawnel F M, et al.
Cell Chemical Biology, 24(5), 624-634 (2017)
Xiaomin Liang et al.
Drug metabolism and disposition: the biological fate of chemicals, 48(12), 1283-1292 (2020-10-11)
It is well documented that human hepatic clearance based on in vitro metabolism or transporter assays systematically resulted in underprediction; therefore, large empirical scalars are often needed in either static or physiologically based pharmacokinetic (PBPK) models to accurately predict human
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A, et al.
British Journal of Haematology, 178(5), 781-793 (2017)
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
King Jr T E, et al.
American Journal of Respiratory and Critical Care Medicine, 177(1), 75-81 (2008)
Mona Bensalah et al.
Journal of cachexia, sarcopenia and muscle, 13(3), 1771-1784 (2022-03-24)
Fibrosis is defined as an excessive accumulation of extracellular matrix (ECM) components. Many organs are subjected to fibrosis including the lung, liver, heart, skin, kidney, and muscle. Muscle fibrosis occurs in response to trauma, aging, or dystrophies and impairs muscle

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门